Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART)
Open Access
- 1 January 2011
- journal article
- research article
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 10 (1) , 94
- https://doi.org/10.1186/1476-511x-10-94
Abstract
Familial hypercholesterolemia (FH) patients are at high risk for premature coronary heart disease (CHD). Despite the use of statins, most patients do not achieve an optimal LDL-cholesterol goal. The aims of this study are to describe baseline characteristics and to evaluate Lipid Lowering Therapy (LLT) in FH patients recruited in SAFEHEART. A cross-sectional analysis of cases recruited in the Spanish FH cohort at inclusion was performed. Demographic, lifestyle, medical and therapeutic data were collected by specific surveys. Blood samples for lipid profile and DNA were obtained. Genetic test for FH was performed through DNA-microarray. Data from 1852 subjects (47.5% males) over 19 years old were analyzed: 1262 (68.1%, mean age 45.6 years) had genetic diagnosis of FH and 590 (31.9%, mean age 41.3 years) were non-FH. Cardiovascular disease was present in 14% of FH and in 3.2% of non-FH subjects (P < 0.001), and was significantly higher in patients carrying a null mutation compared with those carrying a defective mutation (14.87% vs. 10.6%, respectively, P < 0.05). Prevalence of current smokers was 28.4% in FH subjects. Most FH cases were receiving LLT (84%). Although 51.5% were receiving treatment expected to reduce LDL-c levels at least 50%, only 13.6% were on maximum statin dose combined with ezetimibe. Mean LDL-c level in treated FH cases was 186.5 mg/dl (SD: 65.6) and only 3.4% of patients reached and LDL-c under 100 mg/dl. The best predictor for LDL-c goal attainment was the use of combined therapy with statin and ezetimibe. Although most of this high risk population is receiving LLT, prevalence of cardiovascular disease and LDL-c levels are still high and far from the optimum LDL-c therapeutic goal. However, LDL-c levels could be reduced by using more intensive LLT such as combined therapy with maximum statin dose and ezetimibe.Keywords
This publication has 23 references indexed in Scilit:
- Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The NetherlandsAtherosclerosis, 2010
- Efficacy of statins in familial hypercholesterolaemia: a long term cohort studyBMJ, 2008
- Familial hypercholesterolaemia: summary of NICE guidanceBMJ, 2008
- Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry studyEuropean Heart Journal, 2008
- Interpretación de los cuestionarios de salud SF-36 y SF-12 en España: componentes físico y mentalMedicina Clinica, 2008
- Cascade genetic screening for familial hypercholesterolemiaClinical Genetics, 2004
- Using different physical activity measurements in eight European countries. Results of the European Physical Activity Surveillance System (EUPASS) time series surveyPublic Health Nutrition, 2003
- Phenotypic variability in familial hypercholesterolaemia: an updateCurrent Opinion in Lipidology, 2002
- Phenotypic Variation in Heterozygous Familial HypercholesterolemiaArteriosclerosis, Thrombosis, and Vascular Biology, 1998
- Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group.BMJ, 1991